Company Description
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases.
Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.
The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure.
In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors.
Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee’s Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system.
The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016.
Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
| Country | United States |
| Founded | 1992 |
| IPO Date | Aug 8, 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Jed Latkin |
Contact Details
Address: 2600 Kelly Road, Suite 100 Warrington, Pennsylvania 18976-3622 United States | |
| Phone | 215 488 9300 |
| Website | windtreetx.com |
Stock Details
| Ticker Symbol | WINT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000946486 |
| CUSIP Number | 97382D303 |
| ISIN Number | US97382D4025 |
| Employer ID | 94-3171943 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jed A. Latkin | Chief Executive Officer, President and Director |
| Eric L. Curtis M.B.A. | Senior Vice President and Chief Operating Officer |
| Dr. Steven G. Simonson M.D., M.H.S | Senior Vice President and Chief Medical Officer |
| George Cox | Vice President of Technical Operations |
| Dr. Pratap Paruchuru | Executive Director of Clinical Development |
| Tracy Rarick | Head of Operations and Program Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2025 | ARS | Filing |
| Aug 8, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 8, 2025 | 8-K | Current Report |
| Aug 5, 2025 | 8-K | Current Report |
| Aug 4, 2025 | 8-K | Current Report |
| Jul 30, 2025 | PRE 14A | Other preliminary proxy statements |
| Jul 24, 2025 | 8-K | Current Report |
| Jul 17, 2025 | 8-K | Current Report |
| Jul 11, 2025 | EFFECT | Notice of Effectiveness |
| Jul 10, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |